PSMA-Targeted Radiation Drug for Prostate Cancer Subset Meets Study Goal
Treatment with 177Lu-PSMA-I&T in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (CRPC) demonstrated meaningful benefits in radiographic progression-free survival (PFS). 177Lu-PSMA-I& …